Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China

Table 3

The cost effectiveness of glaucoma fixed combinations.

Drug	Study	Study period (days)	Sample size	Age (years)	Gender, female (%)	Baseline IOP (mmHg)	IOP reduction (mmHg)	Total cost (US dollar)	Cost effectiveness ($/mmHg decrease in IOP)
Azarga	Sezgin et al.	92	57	54.8 ± 8.5	56.1	24.6–29.9	6.42–9.74	21.16	2.17–3.30
DuoTrav	Schuman et al.	90	155	62.4 ± 10.9	59.4	22.9–25.6	7.0–8.2	71.10	8.67–10.16
Ganfort	Goldberg et al.	84	283	63.5 (23–86)	57.2	23.8–25.4	7.27–8.55	29.40	3.40–4.04
Xalacom	Shin et al.	92	125	64.0 ± 11.0	53.6	27.9 ± 3.6	9.4 ± 3.1	51.52	4.12–8.18